Global Life Science Ventures

Global Life Science Ventures was a venture capital firmventure capital firm headquartered in Munich, Germany. It was launched in 1996 by heir to Boehringer Mannheim pharmaceutical company, Dr Stefan Engelhorn, along with investments from HypoVereinsbank Group and ING Barings. The firm made early stage investments in the life sciences industry , specifically the medical device and biopharmaceutical sectors. Most of its portfolio companies were spun out of universities and scientific institutions.

Though it had offices in Germany and Switzerland and made investments throughout Europe, it initially sought out investments in the United StatesUnited States life sciences market. Its first fund invested in 18 companies in Europe and the United States. In 2002, the firm announced that it had raised a second fund of €143 million to expand its investments in Europe. The firm closed in 2015 after liquidating its assets.

Though it had offices in Germany and SwitzerlandSwitzerland and made investments throughout Europe, it initially sought out investments in the United States life sciences market. Its first fund invested in 18 companies in Europe and the United States. In 2002, the firm announced that it had raised a second fund of €143 million to expand its investments in Europe. The firm closed in 2015 after liquidating its assets.

Global Life Science Ventures was a venture capital firm headquartered in MunichMunich, Germany. It was launched in 1996 by heir to Boehringer Mannheim pharmaceutical company, Dr Stefan Engelhorn, along with investments from HypoVereinsbank Group and ING Barings. The firm made early stage investments in the life sciences industry , specifically the medical device and biopharmaceutical sectors. Most of its portfolio companies were spun out of universities and scientific institutions.

Global Life Science Ventures was a venture capital firm headquartered in Munich, Germany. It was launched in 1996 by heir to Boehringer Mannheim pharmaceutical company, Dr Stefan Engelhorn, along with investments from HypoVereinsbank Group and ING Barings. The firm made early stage investments in the life sciences industry , specifically the medical device and biopharmaceutical sectors. Most of its portfolio companies were spun out of universities and scientific institutions.

Though it had offices in Germany and Switzerland and made investments throughout Europe, it initially sought out investments in the United States life sciences market. Its first fund invested in 18 companies in Europe and the United States. In 2002, the firm announced that it had raised a second fund of €143 million to expand its investments in Europe. The firm closed in 2015 after liquidating its assets.